Comment on hopkins et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: Subgroup analysis of the IMPOWER150 trial. cancers 2021, 13, 1176

Edouard Auclin; Laura Mezquita; Benjamin Besse

doi:10.3390/cancers13143624

Comment on hopkins et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: Subgroup analysis of the IMPOWER150 trial. cancers 2021, 13, 1176

Edouard Auclin, Laura Mezquita, Benjamin Besse

Research output: Contribution to journal › Comment/debate

2 Citations (Scopus)

Original language	English
Article number	3624
Journal	Cancers
Volume	13
Issue number	14
DOIs	https://doi.org/10.3390/cancers13143624
Publication status	Published - 2 Jul 2021

Access to Document

10.3390/cancers13143624

Cite this

@article{fbb080fde2124df89caa629636c2d5f5,

title = "Comment on hopkins et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: Subgroup analysis of the IMPOWER150 trial. cancers 2021, 13, 1176",

author = "Edouard Auclin and Laura Mezquita and Benjamin Besse",

note = "Funding Information: Acknowledgments: Sarah MacKenzie for the English language review. Laura Mezquita received support from the IASLC Research Fellowship Award (2018), ESMO Translational Research Fellowship (2019) and SEOM retorno de Investigadores (2019); Contrato Juan Rod{\'e}s 2020; Ayuda SEOM-Juan Rod{\'e}s 2020.",

year = "2021",

month = jul,

day = "2",

doi = "10.3390/cancers13143624",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

number = "14",

}

Comment on hopkins et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: Subgroup analysis of the IMPOWER150 trial. cancers 2021, 13, 1176. / Auclin, Edouard; Mezquita, Laura; Besse, Benjamin.
In: Cancers, Vol. 13, No. 14, 3624, 02.07.2021.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Comment on hopkins et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy

T2 - Subgroup analysis of the IMPOWER150 trial. cancers 2021, 13, 1176

AU - Auclin, Edouard

AU - Mezquita, Laura

AU - Besse, Benjamin

N1 - Funding Information: Acknowledgments: Sarah MacKenzie for the English language review. Laura Mezquita received support from the IASLC Research Fellowship Award (2018), ESMO Translational Research Fellowship (2019) and SEOM retorno de Investigadores (2019); Contrato Juan Rodés 2020; Ayuda SEOM-Juan Rodés 2020.

PY - 2021/7/2

Y1 - 2021/7/2

UR - http://www.scopus.com/inward/record.url?scp=85110451537&partnerID=8YFLogxK

U2 - 10.3390/cancers13143624

DO - 10.3390/cancers13143624

M3 - Comment/debate

AN - SCOPUS:85110451537

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 14

M1 - 3624

ER -

Comment on hopkins et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: Subgroup analysis of the IMPOWER150 trial. cancers 2021, 13, 1176

Access to Document

Other files and links

Cite this